These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14650958)

  • 1. [Autoimmune phenomena during interferon-alpha therapy for hematopoietic disorders].
    Iguchi T; Nishimaki J; Kawakubo K; Shimamoto T; Iwase O; Suzuki A; Kuriyama Y; Ito Y; Tauchi T; Yaguchi M; Miyazawa K; Kimura Y; Ohyashiki K
    Gan To Kagaku Ryoho; 2003 Nov; 30(12):1911-6. PubMed ID: 14650958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
    Jabbour E; Kantarjian H; Cortes J; Thomas D; Garcia-Manero G; Ferrajoli A; Faderl S; Richie MA; Beran M; Giles F; Verstovsek S
    Cancer; 2007 Nov; 110(9):2012-8. PubMed ID: 17849460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lupus-like autoimmune disease induced by interferon therapy for myeloproliferative disorders.
    Wandl UB; Nagel-Hiemke M; May D; Kreuzfelder E; Kloke O; Kranzhoff M; Seeber S; Niederle N
    Clin Immunol Immunopathol; 1992 Oct; 65(1):70-4. PubMed ID: 1382910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa].
    Tóthová E; Stecová N; Kafková A; Fricová M; Svorcová E
    Vnitr Lek; 2002 May; 48(5):380-3. PubMed ID: 12061203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral response to recombinant interferon-alpha 2b in patients receiving recombinant interferon-alpha 2b therapy.
    von Wussow P; Jakschies D; Freund M; Deicher H
    J Interferon Res; 1989 Sep; 9 Suppl 1():S25-31. PubMed ID: 2809276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment with lymphoblastoid alpha interferon in patients with chronic myeloid leukemia refractory to recombinant interferon alpha 2].
    Steegmann JL; Granados E; Vázquez L; de la Cámara R; Peñarrubia MJ; Fernández-Contreras E; Quiroga JA; Fernández Rañada JM
    Sangre (Barc); 1998 Oct; 43(5):443-6. PubMed ID: 9868341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha.
    Wussow PV; Jakschies D; Freund M; Hehlmann R; Brockhaus F; Hochkeppel H; Horisberger M; Deicher H
    Br J Haematol; 1991 Jun; 78(2):210-6. PubMed ID: 2064959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-alpha.
    Steegmann JL; Requena MJ; Martín-Regueira P; De La Cámara R; Casado F; Salvanés FR; Fernández Rañada JM
    Am J Hematol; 2003 Mar; 72(3):170-6. PubMed ID: 12605388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune mediated thrombocytopenia associated with the use of interferon-alpha in chronic myeloid leukemia.
    Zuffa E; Vianelli N; Martinelli G; Tazzari P; Cavo M; Tura S
    Haematologica; 1996; 81(6):533-5. PubMed ID: 9009441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-mediated and unusual complications during interferon alfa therapy in chronic myelogenous leukemia.
    Sacchi S; Kantarjian H; O'Brien S; Cohen PR; Pierce S; Talpaz M
    J Clin Oncol; 1995 Sep; 13(9):2401-7. PubMed ID: 7666100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comparison of therapeutic effects of low-dose versus high-dose interferon alpha-2b treatment on chronic myelocytic leukemia: a prospective randomized study].
    Du JW; Zhu P; Tian D; Dong ZR; Yang SL; Li SB; Tang YH; Liu H; Cen XN; Zhang Y; Zhu Q; Zhu YL; Yang Y; Wang DX; Wang Z; Cui H; Ma YG; Chen WM; Liu FQ; Ma J; Wang JW; Shen T; Da WM
    Zhonghua Yi Xue Za Zhi; 2005 May; 85(19):1305-9. PubMed ID: 16029627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to sequential treatment with lymphoblastoid interferon-alpha in patients with Ph+ chronic myeloid leukemia unresponsive to recombinant interferon-alpha (rIFN alpha 2a) and neutralizing-rIFN alpha 2a antibodies negative.
    Russo D; Candoni A; Grattoni R; Minisini R; Rosti G
    Haematologica; 1997; 82(3):348-50. PubMed ID: 9234589
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of BCR-ABL transcripts in CML patients in cytogenetic remission after interferon-alpha-based therapy.
    Martinelli G; Testoni N; Amabile M; Bonifazi F; De Vivo A; Farabegoli P; Terragna C; Montefusco V; Ottaviani E; Saglio G; Russo D; Baccarani M; Rosti G; Tura S
    Bone Marrow Transplant; 2000 Apr; 25(7):729-36. PubMed ID: 10745258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of cytogenetic response in Ph+ chronic myeloid leukemia patients treated with interferon alpha].
    Hong H; Qiu JY; Lai YY; Shi Y; He Q; Dang H; Lu DP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):269-73. PubMed ID: 12844411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.
    Tóthová E; Fricová M; Kafková A; Stecová N; Guman T; Raffac S; Hlebasková M
    Neoplasma; 2000; 47(2):125-8. PubMed ID: 10985480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells.
    Müller-Tidow C; Kiehl M; Sindermann JR; Probst M; Banger N; Zühlsdorf M; Chou TC; Berdel WE; Serve H; Koch OM
    Int J Oncol; 2003 Jul; 23(1):151-8. PubMed ID: 12792788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of thyroid autoimmunity after administration of recombinant human interferon-alpha 2b for chronic viral hepatitis.
    Chung YH; Shong YK
    Am J Gastroenterol; 1993 Feb; 88(2):244-7. PubMed ID: 8424429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Monitoring of the therapeutic response of interferon to chronic myeloid leukemia by duel-color fluorescence in situ hybridization].
    Song YQ; Li W; Kong LH; Wang GJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Feb; 11(1):38-40. PubMed ID: 12667287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential treatment of Ph-positive chronic myeloid leukemia with interferon gamma and interferon alpha.
    Russo D; Fanin R; Zuffa E; Damiani D; Gallizia C; Michieli M; Testoni N; Benfenati D; Visani G; Zaccaria A
    Haematologica; 1990; 75(4):334-9. PubMed ID: 2125966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
    Garcia-Manero G; Talpaz M; Giles FJ; Cortes J; Faderl S; O'Brien S; Thomas D; Verstovsek S; Beth Rios M; Shan J; Ferrajoli A; Wierda W; Kantarjian HM
    Cancer; 2003 Jun; 97(12):3010-6. PubMed ID: 12784336
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.